Skip to main content

Table 6 Clinical trials of crenolanib for AML therapy

From: FLT3 inhibitors in acute myeloid leukemia

Study agents

Other agents

Disease

Dose

No Pts

Response

Reference

Crenolanib

Cytarabine

Anthracycline

Untreated

100 mg TID

25

CR 88%

CR/CRi 96%

[62]

Crenolanib

Cytarabine

Anthracycline

Untreated

100 mg TID

29

CR 83%

[63]

Crenolanib

Cytarabine

Mitoxantrone

Relapsed

Refractory

100 mg TID

8

CR 67%

[64]

Crenolanib

Idarubicin

Cytarabine

Relapsed

Refractory

60/80/100 mg

TID

13

ORR 36%

[65]

Crenolanib

 

Relapsed

Refractory

200 mg/m2/day

10

ORR 47%

[66]

  1. ORR overall response rate, CR complete remission, CRi complete remission with incomplete count recovery